- Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
- Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
- Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
- Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
- Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
More ▼
Key statistics
On Thursday, Nuvalent Inc (NUVL:NSQ) closed at 75.09, -16.00% below its 52-week high of 89.39, set on Mar 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 75.34 |
---|---|
High | 76.20 |
Low | 73.75 |
Bid | 71.34 |
Offer | 78.70 |
Previous close | 76.64 |
Average volume | 443.55k |
---|---|
Shares outstanding | 64.07m |
Free float | 51.99m |
P/E (TTM) | -- |
Market cap | 4.91bn USD |
EPS (TTM) | -2.16 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼